163 related articles for article (PubMed ID: 22262591)
1. Design considerations in an active medical product safety monitoring system.
Gagne JJ; Fireman B; Ryan PB; Maclure M; Gerhard T; Toh S; Rassen JA; Nelson JC; Schneeweiss S
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():32-40. PubMed ID: 22262591
[TBL] [Abstract][Full Text] [Related]
2. When should case-only designs be used for safety monitoring of medical products?
Maclure M; Fireman B; Nelson JC; Hua W; Shoaibi A; Paredes A; Madigan D
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():50-61. PubMed ID: 22262593
[TBL] [Abstract][Full Text] [Related]
3. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
[TBL] [Abstract][Full Text] [Related]
4. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
Platt R; Carnahan RM; Brown JS; Chrischilles E; Curtis LH; Hennessy S; Nelson JC; Racoosin JA; Robb M; Schneeweiss S; Toh S; Weiner MG
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():1-8. PubMed ID: 22262586
[TBL] [Abstract][Full Text] [Related]
5. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system.
Rassen JA; Schneeweiss S
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():41-9. PubMed ID: 22262592
[TBL] [Abstract][Full Text] [Related]
6. Design considerations, architecture, and use of the Mini-Sentinel distributed data system.
Curtis LH; Weiner MG; Boudreau DM; Cooper WO; Daniel GW; Nair VP; Raebel MA; Beaulieu NU; Rosofsky R; Woodworth TS; Brown JS
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():23-31. PubMed ID: 22262590
[TBL] [Abstract][Full Text] [Related]
7. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.
Cook AJ; Tiwari RC; Wellman RD; Heckbert SR; Li L; Heagerty P; Marsh T; Nelson JC
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():72-81. PubMed ID: 22262595
[TBL] [Abstract][Full Text] [Related]
8. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
Maro JC; Brown JS
Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
[TBL] [Abstract][Full Text] [Related]
9. A policy framework for public health uses of electronic health data.
McGraw D; Rosati K; Evans B
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():18-22. PubMed ID: 22262589
[TBL] [Abstract][Full Text] [Related]
10. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
[No Abstract] [Full Text] [Related]
11. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
[TBL] [Abstract][Full Text] [Related]
12. Methodologic challenges to studying patient safety and comparative effectiveness.
Strom BL
Med Care; 2007 Oct; 45(10 Supl 2):S13-5. PubMed ID: 17909371
[TBL] [Abstract][Full Text] [Related]
13. Epidemiologic studies: pitfalls in interpretation.
Westhoff CL
Dialogues Contracept; 1995; 4(5):5-6, 8. PubMed ID: 12288680
[TBL] [Abstract][Full Text] [Related]
14. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.
Fireman B; Toh S; Butler MG; Go AS; Joffe HV; Graham DJ; Nelson JC; Daniel GW; Selby JV
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():282-90. PubMed ID: 22262618
[TBL] [Abstract][Full Text] [Related]
15. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
16. Electronic healthcare databases for active drug safety surveillance: is there enough leverage?
Coloma PM; Trifirò G; Schuemie MJ; Gini R; Herings R; Hippisley-Cox J; Mazzaglia G; Picelli G; Corrao G; Pedersen L; van der Lei J; Sturkenboom M;
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):611-21. PubMed ID: 22315152
[TBL] [Abstract][Full Text] [Related]
17. A potential causal association mining algorithm for screening adverse drug reactions in postmarketing surveillance.
Ji Y; Ying H; Dews P; Mansour A; Tran J; Miller RE; Massanari RM
IEEE Trans Inf Technol Biomed; 2011 May; 15(3):428-37. PubMed ID: 21435986
[TBL] [Abstract][Full Text] [Related]
18. The London low emission zone baseline study.
Kelly F; Armstrong B; Atkinson R; Anderson HR; Barratt B; Beevers S; Cook D; Green D; Derwent D; Mudway I; Wilkinson P;
Res Rep Health Eff Inst; 2011 Nov; (163):3-79. PubMed ID: 22315924
[TBL] [Abstract][Full Text] [Related]
19. Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerations.
Brown JS; Kulldorff M; Petronis KR; Reynolds R; Chan KA; Davis RL; Graham D; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):226-34. PubMed ID: 19148879
[TBL] [Abstract][Full Text] [Related]
20. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned.
Carnahan RM; Moores KG
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():82-9. PubMed ID: 22262596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
